A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

Phase 1/2 Active not recruiting 42 enrolled Rznomics, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

This is first in human study to evaluate the safety, tolerability, immunogenicity, and preliminary clinical activity of RZ-001 when given to subjects with human telomerase reverse transcriptase (hTERT)-positive HCC.

Timeline

Start: 2022-07-29
Primary completion: 2029-03
Completion: 2029-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RZ-001	Unknown	—	Intrathecal
Background	Valganciclovir	Small molecule	—	—

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

Summary

Timeline

Drugs

Indications